<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001714</url>
  </required_header>
  <id_info>
    <org_study_id>2013-204</org_study_id>
    <secondary_id>1R01AG043383-01A1</secondary_id>
    <nct_id>NCT02001714</nct_id>
  </id_info>
  <brief_title>Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms</brief_title>
  <acronym>Gladiolus</acronym>
  <official_title>Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ananias Diokno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This three-site randomized controlled trial compares the effectiveness and cost-effectiveness
      of a group-administered behavioral treatment program to no treatment. Women with stress,
      urgency, or mixed urinary incontinence will be recruited and screened centrally, evaluated
      clinically at each of three study sites, and random assigned to one of two treatment arms: 1.
      Group behavioral treatment or 2. No treatment. Group treatment modalities have the potential
      to reach a larger population of older women with urinary incontinence, not only in the
      traditional medical settings, but also in community settings. The investigators hypothesize
      that group behavioral treatment will be more effective than no treatment. The investigators
      hypothesize that the group treatment will be cost-effective compared to no treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization schedule will be concealed so that investigators and staff at the sites will not be able to anticipate experimental group assignments. Evaluators at each site will be blind to group assignment throughout all assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity.</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The primary outcome is the self-reported urinary incontinence severity as measured by the International Consultation on Incontinence questionnaire-short form (ICI-Q). This short and simple questionnaire is used to screen for incontinence (urine leakage) to obtain a brief yet comprehensive summary of the level, impact and perceived cause of symptoms of incontinence. The ICI-Q consists of four questions and numeric scales: 1. How much do you leak urine? (0-5); never - all the time, 2. How much urine do you usually leak? (0-6); none - large amount, 3. Overall, how much does leaking urine interfere with your everyday life? (0-10); not at all - a great deal, 4. When does urine leak? Multiple choices. The ICI-Q score is the sum of questions 1-3 and ranges from 0-21. The higher the score, the greater severity of incontinence. Baseline data is compared to the 3 month data for the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group Behavioral Treatment Cost-effectiveness</measure>
    <time_frame>12 months</time_frame>
    <description>Measure resource use and utilities and compare the difference in incontinence management costs and utilities between treatment and control group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Urinary Incontinence, Stress</condition>
  <condition>Urinary Incontinence, Urge</condition>
  <arm_group>
    <arm_group_label>Group Behavioral Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will attend a group behavioral treatment class and follow-up visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not attend group behavioral treatment class.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group Behavioral Treatment</intervention_name>
    <description>Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.</description>
    <arm_group_label>Group Behavioral Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female

          2. Aged 55 years or older

          3. Ability to understand, read and write English

          4. Stress, urgency, or mixed urgency and stress urinary incontinence (UI) (by self
             report)

          5. On the International Consultation on Incontinence Modular Questionnaire - Short Form
             (ICIQ UI-SF), frequency of leakage at least a 1 (&quot;about once a week or less often&quot;) on
             item #1 and volume of urine loss at least a 2 (&quot;a small amount&quot;) on item #2.

          6. Symptoms of three months duration or longer (on history)

          7. Passing score (i.e., categorized as &quot;probably not demented&quot;) on the MiniCog Test

          8. Timed &quot;Up and Go&quot; Test (TUG) score of 20 seconds or less

          9. Willing to undergo vaginal/pelvic examination

         10. Signed informed consent form

        Exclusion Criteria:

          1. History of renal, bladder, uterine, ovarian, urethral, anal or rectal cancer,
             radiation therapy to the pelvis for any cancer/malignancy, or any active
             cancer/malignancy (except skin cancer)

          2. Non-ambulatory (participant confined to bed or wheelchair)

          3. Persistent pelvic pain (defined as daily pelvic pain &gt; 3 months)

          4. History of neurologic or end-stage diseases (e.g. cerebral vascular accident (CVA),
             Parkinson's disease, multiple sclerosis, epilepsy, spinal cord tumor or trauma, spina
             bifida, symptomatic herniated disc)

          5. Previous treatment or current participation in a research study for UI, including
             surgery or formal behavioral treatment (pelvic floor muscle training, biofeedback,
             pelvic floor electrical stimulation, percutaneous tibial nerve stimulation, sacral
             neuromodulation, botox or other periurethral injection)

          6. Currently taking urinary incontinence or overactive bladder medications

          7. History of other urinary conditions or procedures that may affect continence status
             (e.g. urethral diverticula, previous augmentation cystoplasty or artificial urinary
             sphincter; implanted nerve stimulators for urinary symptoms)

          8. Participation in any drug/device research study.

          9. Pelvic organ prolapse protruding past the introitus (at rest or persisting after
             strain)

         10. Evidence of urinary tract infection (UTI) by urine dipstick (leukocytes +1 or greater,
             nitrites +1 or greater, leukocytes alone (w/o nitrites) +2 or greater, or presence of
             hematuria &gt; +1). Participants may be re-screened after treatment with antibiotics or
             if hematuria work-up is negative.

         11. History of 2 or more recurrent UTI's within the past year; more than one UTI within
             past 6 months

         12. Post void residual urine volume 150 cc or more.

         13. Unstable medical condition (as determined by site PI)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ananias C Diokno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham VA Medical Cnter</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System, Urology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <results_first_submitted>July 25, 2017</results_first_submitted>
  <results_first_submitted_qc>October 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2017</results_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Ananias Diokno</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment letters were mailed to women 55 years and older seeking women with urinary incontinence who were treatment na√Øve. Those that met preliminary screening criteria, done at the administrative site, were referred to one of the three clinical sites (Alabama, Michigan or Pennsylvania) for final screening and enrollment .</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group Behavioral Treatment</title>
          <description>Participants will attend a group behavioral treatment class and follow-up visits.
Group Behavioral Treatment: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Subjects will not attend group behavioral treatment class but have the same follow-up visit schedule. Subjects will receive the same handout.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group Behavioral Treatment</title>
          <description>Participants will attend a group behavioral treatment class and follow-up visits.
Group Behavioral Treatment: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Subjects will not attend group behavioral treatment class but have the same follow-up visit schedule. Subjects will receive the same handout.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="6.8"/>
                    <measurement group_id="B2" value="65" spread="7.7"/>
                    <measurement group_id="B3" value="64" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity.</title>
        <description>The primary outcome is the self-reported urinary incontinence severity as measured by the International Consultation on Incontinence questionnaire-short form (ICI-Q). This short and simple questionnaire is used to screen for incontinence (urine leakage) to obtain a brief yet comprehensive summary of the level, impact and perceived cause of symptoms of incontinence. The ICI-Q consists of four questions and numeric scales: 1. How much do you leak urine? (0-5); never - all the time, 2. How much urine do you usually leak? (0-6); none - large amount, 3. Overall, how much does leaking urine interfere with your everyday life? (0-10); not at all - a great deal, 4. When does urine leak? Multiple choices. The ICI-Q score is the sum of questions 1-3 and ranges from 0-21. The higher the score, the greater severity of incontinence. Baseline data is compared to the 3 month data for the primary outcome.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>The Group Behavioral Treatment group population at baseline is 232. At the 3 month follow-up visit 16 had withdrawn and 7 missed the appointment, leaving 209 for the total number analyzed. For the No Treatment group, the number at baseline is 231 and by the 3 month visit 8 had withdrawn and another 11 missed the appointment, leaving 212.</population>
        <group_list>
          <group group_id="O1">
            <title>Group Behavioral Treatment</title>
            <description>Participants will attend a group behavioral treatment class and follow-up visits.
Group Behavioral Treatment: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects will not attend group behavioral treatment class but have the same follow-up visit schedule. Subjects will receive the same handout.</description>
          </group>
        </group_list>
        <measure>
          <title>Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity.</title>
          <description>The primary outcome is the self-reported urinary incontinence severity as measured by the International Consultation on Incontinence questionnaire-short form (ICI-Q). This short and simple questionnaire is used to screen for incontinence (urine leakage) to obtain a brief yet comprehensive summary of the level, impact and perceived cause of symptoms of incontinence. The ICI-Q consists of four questions and numeric scales: 1. How much do you leak urine? (0-5); never - all the time, 2. How much urine do you usually leak? (0-6); none - large amount, 3. Overall, how much does leaking urine interfere with your everyday life? (0-10); not at all - a great deal, 4. When does urine leak? Multiple choices. The ICI-Q score is the sum of questions 1-3 and ranges from 0-21. The higher the score, the greater severity of incontinence. Baseline data is compared to the 3 month data for the primary outcome.</description>
          <population>The Group Behavioral Treatment group population at baseline is 232. At the 3 month follow-up visit 16 had withdrawn and 7 missed the appointment, leaving 209 for the total number analyzed. For the No Treatment group, the number at baseline is 231 and by the 3 month visit 8 had withdrawn and another 11 missed the appointment, leaving 212.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-4" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-2" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Group Behavioral Treatment Cost-effectiveness</title>
        <description>Measure resource use and utilities and compare the difference in incontinence management costs and utilities between treatment and control group.</description>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from enrollment through the one year follow-up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group Behavioral Treatment</title>
          <description>Participants will attend a group behavioral treatment class and follow-up visits.
Group Behavioral Treatment: Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Subjects will not attend group behavioral treatment class but have the same follow-up visit schedule. Subjects will receive the same handout.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ananias C. Diokno, MD</name_or_title>
      <organization>Beaumont Health</organization>
      <email>ananias.diokno@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

